Sponsored Content: She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory expertise, nimbleness, consulting and strategy skills, modeling and biostatistics knowhow, and more.

Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.

Michael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how companies have been trading, and their ability to raise money, off of data.

He gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and carefully, and why he decided to launch City Therapeutics.

He discusses BridgeBio, Cytokinetics, Wave, Vaxcyte, Iovance, Unity, and Enliven.

He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's non-dilutive financing could help Stoke realize its goal to be a platform company.

Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdystrophin expression down to muscle integrity are important and pointed in the right direction. Plus, why the company secured a $200M raise before releasing the data publicly.

Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture.

CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy program, while CSO Sara Prickett explains how the peptide approach aims to teach T-cells to correct allergies while not setting off allergic inflammation that today's therapies do.

CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ovarian cancer.

He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.

CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program targeting BRD9, and how the company thinks about partnerships going forward.

Co-Founder and CEO Sam Windsor describes the rationale for using AI to focus more on tox, not efficacy, and gives and example of a drug the company has already in-licensed from a pharma company. Plus, what today's raise will enable the company to do.

CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese partner, an IL18, ZIP12, and more.

Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the improvements in vector delivery capabilities, and improving the yield and lowering the cost of future treatments, that is possible with the latest generation of gene therapy.

He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus, comments on Structure Therapeutics, Corbus, Skye Bioscience, Zealand, Viking, Altimmune, Terns, and BioAge Labs.

Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25% higher recovery rate compared to standard treatment.

He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance of good murine models, and his take on Chinese competition.

Co-Founder and CEO Peter Joyce describes the science behind this, including how the company's lead programs inhibit Endoplasmic Reticulum Associated Proteases (ERAPs). A clinical stage company, he describes Greywolf's clinical experience and fundraising history.

CEO Jame Mcllroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to read out immanently.

Professor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital dermatology, and invites companies to run clinical trials in Scotland.

From the big HumanX AI conference in Las Vegas, he describes the overall path he sees AI taking in its contributions to drug development, and gives an update on Generate's programs regarding TSLP, IL13, ADCs, and more.

Co-Founder & CEO Douglas Thomson describes how the company was founded, and walks us through the science. Plus, a recap of recently presented phase 2 data, and the road ahead.

CEO Steven Powell joins BiotechTV from Scotland's Life Sciences Conference and Awards in Glasgow, and explains Glen Clova's expertise in making next generation VLPs. The first clinical program will be in senile pruritus, targeting IL-31.

He describes the assets that Scotland has to offer the industry such as excellent universities that derive innovation and a diverse population that makes it a great region for clinical trials.

Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it. Plus, the growth of the company, investor support, and being based in Glasgow.

She describes The Bank's goal of supporting life sciences in Scotland and making a societal impact, how it aims to co-invest with likeminded investors. Plus, examples of investments such as Elasmogen and PneumoWave.

Professor Cullis, one of the original pioneers of LNPs and co-founder of 11 biotechnology companies, describes the challenge of successfully using lipid nanoparticles to deliver payloads to places outside of the liver. Jay Kulkarni, a former postdoc of his who is co-founder and CSO of the company, describes the 'one-stop-shop' capabilities of NanoVation, which has already led to a partnership with Novo Nordisk and others.

CEO Ken Macnamara describes the science behind this idea and discusses recently presented preclinical data. He highlights the lead program for glioblastoma and plans for the future, and also explains how he believes a patient sample biobank Trogenix has built is key to the company's success in research.

Co-Founder and CEO Michalis Papadakis describes the unmet need for a quick, accurate assessment of stroke damage by front line physicians, who otherwise might not be experts in the area. Plus, moving the technology to lung disease and beyond.

Andrew McNeill, Managing Partner of St. Andrews based Eos Advisory, introduces us to the firm and some portfolio companies including Dxcover and Laverock Therapeutics.

Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.

Founder & CEO Clare Wareing describes the company's design, with an eye towards being capital efficient and investing over and again for the long-term. She describes the lead investments: a PARG inhibitor, GPR68 small molecules, and a GTPase inhibitor.

CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit (PPU). The first goal is to go after hard to treat solid tumors.

Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE has also completed a phase 1a with Tay's oral selective BET inhibitor. Plus, how Tay is also working on a small molecule gene therapy program.

Founder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been built and the work that takes place at the centre, including founding companies like Amphista Therapeutics. Plus, his take on the field more broadly and targets that researchers are going after.

Charlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their pharma partnerships and licenses, and cases where independent biotech companies have spun out of the work.

He discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU), the Drug Discovery Unit, the soon-to-open Innovation Hub, and more.

Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second quarter. Plus, ulcerative colitis data that will be out in the fourth quarter and the opportunity there. He also highlights the company's PD-1 for oncology that is commercialized by GSK.

He sets the table for upcoming readouts from Axsome, Vigil Neuro, Verastem, Corvus, and Harmony Biosciences.

CEO Nima Alidoust and CSO Johnny Yu describe Vevo's contribution of 100M cells, plus a 60,000 drug-patient interaction map, that has been combined with Arc's 200M cell gene expression data from 21 different species (scBaseCamp). They explain the size and scale of this now open source atlas, and the potential utility of it to outside researchers.

Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle cell disease that is now called CASGEVY. He describes what it was like receiving the treatment, and discusses the need for more awareness and access in the sickle cell community worldwide for this type of treatment.

Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good Therapeutics, and how the follow-on company Bonum aims to test this approach more broadly. He describes how it works, and discusses the initial programs they have chosen, with a LAG3-IL2 being the most advanced.

He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on portfolio companies eGenesis and Vir Biotechnology.

Celebrating with the Seattle (and beyond) biotech community.

He describes the 14th fund that Atlas raised at the end of last year, which was $450 million. Plus, his take on the environment, regulatory changes, China's impact on the sector, and improving biopharma's image.

She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs.

He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing.

She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its lead SMARCA2 program (partnered with Lilly), and discusses what she would like to see out of future phase 1 data.

He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs.